Athersys (ATHX) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock ATHX vs. GLTO, KZIA, HEPA, SPRC, ARAV, ENVB, RDHL, SNPX, REVB, and MTNBShould you be buying Athersys stock or one of its competitors? The main competitors of Athersys include Galecto (GLTO), Kazia Therapeutics (KZIA), Hepion Pharmaceuticals (HEPA), SciSparc (SPRC), Aravive (ARAV), Enveric Biosciences (ENVB), RedHill Biopharma (RDHL), Synaptogenix (SNPX), Revelation Biosciences (REVB), and Matinas Biopharma (MTNB). These companies are all part of the "pharmaceutical preparations" industry. Athersys vs. Galecto Kazia Therapeutics Hepion Pharmaceuticals SciSparc Aravive Enveric Biosciences RedHill Biopharma Synaptogenix Revelation Biosciences Matinas Biopharma Galecto (NASDAQ:GLTO) and Athersys (NASDAQ:ATHX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, earnings, dividends, community ranking, profitability, institutional ownership, risk, analyst recommendations and valuation. Does the MarketBeat Community believe in GLTO or ATHX? Athersys received 333 more outperform votes than Galecto when rated by MarketBeat users. However, 60.38% of users gave Galecto an outperform vote while only 56.33% of users gave Athersys an outperform vote. CompanyUnderperformOutperformGalectoOutperform Votes3260.38% Underperform Votes2139.62% AthersysOutperform Votes36556.33% Underperform Votes28343.67% Do analysts recommend GLTO or ATHX? Galecto presently has a consensus target price of $10.00, suggesting a potential upside of 257.14%. Given Galecto's stronger consensus rating and higher probable upside, research analysts plainly believe Galecto is more favorable than Athersys.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galecto 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Athersys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is GLTO or ATHX more profitable? Athersys' return on equity of 0.00% beat Galecto's return on equity.Company Net Margins Return on Equity Return on Assets GalectoN/A -76.96% -66.59% Athersys N/A N/A -223.03% Does the media prefer GLTO or ATHX? In the previous week, Galecto and Galecto both had 1 articles in the media. Galecto's average media sentiment score of 1.87 beat Athersys' score of 0.00 indicating that Galecto is being referred to more favorably in the media. Company Overall Sentiment Galecto Very Positive Athersys Neutral Which has stronger valuation and earnings, GLTO or ATHX? Galecto has higher earnings, but lower revenue than Athersys. Galecto is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGalectoN/AN/A-$38.35M-$18.61-0.15Athersys$146K0.00-$72.53M-$2.03N/A Which has more risk and volatility, GLTO or ATHX? Galecto has a beta of 1.28, meaning that its share price is 28% more volatile than the S&P 500. Comparatively, Athersys has a beta of -0.9, meaning that its share price is 190% less volatile than the S&P 500. Do institutionals and insiders believe in GLTO or ATHX? 14.2% of Galecto shares are owned by institutional investors. Comparatively, 19.4% of Athersys shares are owned by institutional investors. 11.9% of Galecto shares are owned by insiders. Comparatively, 0.0% of Athersys shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryGalecto beats Athersys on 9 of the 15 factors compared between the two stocks. Get Athersys News Delivered to You Automatically Sign up to receive the latest news and ratings for ATHX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATHX vs. The Competition Export to ExcelMetricAthersysPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$833,000.00$6.89B$5.56B$7.82BDividend YieldN/A3.05%5.11%4.22%P/E Ratio0.007.4422.5118.48Price / SalesN/A242.70395.68103.60Price / CashN/A65.8538.1834.62Price / BookN/A6.516.774.25Net Income-$72.53M$143.21M$3.22B$248.23M Athersys Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATHXAthersysN/AN/AN/AN/A$833,000.00$146,000.000.0024Analyst ForecastNews CoverageGLTOGalecto3.1118 of 5 stars$2.42-0.4%$10.00+313.2%-83.7%$3.20MN/A-0.1340Upcoming EarningsPositive NewsKZIAKazia Therapeutics3.7785 of 5 stars$3.09-6.4%$11.50+272.2%-78.6%$3.11M$2.31M0.0012Positive NewsHEPAHepion Pharmaceuticals0.2703 of 5 stars$0.27-16.2%N/A-99.6%$2.96MN/A-0.0620News CoverageGap DownSPRCSciSparc0.965 of 5 stars$0.27-3.4%N/A-80.5%$2.96M$1.75M0.004Short Interest ↓Positive NewsARAVAraviveN/A$0.04flatN/AN/A$2.95M$6.99M0.0020High Trading VolumeENVBEnveric Biosciences2.6494 of 5 stars$1.19+1.7%$10.00+740.3%-90.6%$2.94MN/A-0.0320Positive NewsRDHLRedHill Biopharma1.0685 of 5 stars$2.17-4.0%N/A-99.2%$2.89M$8.04M0.00210Analyst ForecastGap DownSNPXSynaptogenix2.7766 of 5 stars$2.05-3.3%$14.00+582.9%-48.7%$2.85MN/A-0.194Positive NewsGap DownREVBRevelation Biosciences0.4587 of 5 stars$3.14+1.9%N/A-91.0%$2.84MN/A-0.0110Short Interest ↑Negative NewsGap UpMTNBMatinas BiopharmaN/A$0.56-7.2%N/A+218.3%$2.83M$1.10M-0.1130 Related Companies and Tools Related Companies Galecto Competitors Kazia Therapeutics Competitors Hepion Pharmaceuticals Competitors SciSparc Competitors Aravive Competitors Enveric Biosciences Competitors RedHill Biopharma Competitors Synaptogenix Competitors Revelation Biosciences Competitors Matinas Biopharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATHX) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Athersys, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Athersys With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.